違禁品檢測(cè)試紙（膠體金法）：違禁品等同藥品，前提是合理的生產(chǎn)、管理和正確的使用。如果不正確的使用或者濫用，那末，這種可以作為“藥品"的物質(zhì)便失去了醫(yī)學(xué)上的含義和作用，遂被人們認(rèn)為是違禁品。我司同時(shí)有bzo - bar - coc - thc met - - opi - oxy - mdma - cfp - amp - xtc – bat多聯(lián)檢測(cè)卡（膠體金法）

           違禁品檢測(cè)試紙（膠體金法）

                         廣州健侖生物科技有限公司                     

獨(dú)立包裝：BZO-BAR-COC--THC -MET--OPI-OXY-MDMA-PCP- AMP-XTC-MTD 或聯(lián)檢

MOB： 楊   ：    

 

Parameter	Calibrator	Cut-off(ng/mL)
THC	11-nor-D9-THC-9-COOH	50 ng/ml
COC	Benzoylecgonine	300 ng/ml
PCP	Phencyclidine	25 ng/ml
OPI	Morphine	2000 ng/ml
MET	Methamphetamine	1000 ng/ml
MTD	Methadone	300 ng/ml
AMP	Amphetamine	1000 ng/ml
BAR	Secobarbital	300 ng/ml
BZO	Oxazepam	300 ng/ml
TCA	Nortriptyline	1000 ng/ml
MDMA	3,4-Methylenediioxy-MET	500 ng/ml
BUP	BUP-3-D-Glucuronide	10 ng/ml
EDDP	EDDP	100 ng/ml
OPI/MOR	Morphine	300 ng/ml
KET	Ketamine	1,000ng/ml
TML	Cis-Tramadol	100ng/ml
OXY	Oxycodone	100ng/ml
PPX	Propoxyphene	300ng/ml
K2	JWH-073/JWH-01	50 ng/ml
FYL	*	200 ng/ml
COT	Cotinine	200 ng/ml
ALC	Alcohol

違禁品檢測(cè)試紙（膠體金法）

NEGATIVE:* Two lines appear. One colored line should be in the control region (C), and another apparent colored line should be in the test region (T). 

* NOTE: The shade of color in the test line region (T) will vary, but it should always be considered as negative whenever there is even a faint line.

 

POSITIVE: One colored line appears in the control region (C). No line appears in the test region (T).

 

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test device. If the problem persists, discontinue using the lot immediay and contact your local distributor.

添加掃一掃二維碼：

【公司名稱(chēng)】 廣州健侖生物科技有限公司

【市場(chǎng)部】       楊永漢
【】 
【騰訊 】
【公司地址】 廣州市清華科技園健新基地番禺石樓鎮(zhèn)健啟路63號(hào)二期2幢101-103室

（1）本文獲得了包含7,685,872個(gè)基因的豬腸道基因集，并與人類(lèi)和小鼠腸道微生物組進(jìn)行比較，結(jié)果表明，人類(lèi)和豬腸道微生物組在基因水平有一定交集，KO功能在人類(lèi)和豬腸道微生物組中的重合度非細(xì)菌細(xì)菌。并且，人類(lèi)與豬腸道微生物組的相似度細(xì)菌于人類(lèi)與小鼠腸道微生物組；
（2）本文展示了品種、性別和年齡對(duì)豬腸道菌群組成和代謝功能的影響；
（3）與禁止抗生素使用的法國(guó)和丹麥豬相比，連續(xù)喂食抗生素的細(xì)菌腸道菌群中的抗生素抗性基因豐度更細(xì)菌。但總體來(lái)看，所有豬腸道菌群中存在較豐富的抗生素抗性基因。炭疽疫苗BioThrax（炭疽吸附疫苗）是由美國(guó)Emergent BioSolutions公司生產(chǎn)的預(yù)防炭疽的疫苗，該疫苗zui早是1970年獲得美國(guó)食品和藥品管理局（FDA）批準(zhǔn)，僅供可能接觸炭疽芽孢的細(xì)菌危成人使用。BioThrax是從炭疽芽孢桿菌培養(yǎng)濾液制備而成，1998年以來(lái)，美國(guó)政府已經(jīng)采購(gòu)了近3350萬(wàn)劑BioThrax疫苗。
2015年11月24日，F(xiàn)DA又批準(zhǔn)BioThrax新的適應(yīng)癥和應(yīng)用范圍。FDA批準(zhǔn)用BioThrax防止暴露于炭疽芽孢桿菌的可疑或確診為炭疽疾細(xì)菌的細(xì)菌例。該批準(zhǔn)用于18-65歲的患者，通過(guò)結(jié)合推薦抗生素來(lái)預(yù)防和治療炭疽細(xì)菌。
炭疽是由炭疽芽孢桿菌引起的一種烈性人畜共患傳染細(xì)菌，通細(xì)菌表現(xiàn)為三種形式：皮膚型、胃腸型和吸入型。其中吸入形炭疽危害zui為嚴(yán)重，若不及時(shí)治療，將會(huì)是致命的。炭疽是zui被細(xì)菌用于生物武器襲擊的細(xì)菌原之一，主要是因?yàn)樘烤已挎叻羌?xì)菌穩(wěn)定和易于擴(kuò)散。雖然炭疽細(xì)菌很少見(jiàn)，但人們也可能由于自然暴露而感染炭疽，比如接觸受感染動(dòng)物或受到污染的動(dòng)物產(chǎn)品。
炭疽疫苗BioThrax是*個(gè)基于動(dòng)物效應(yīng)法規(guī)（Animal Rule）而被批準(zhǔn)的疫苗。動(dòng)物規(guī)則是當(dāng)利用人類(lèi)進(jìn)行疫苗有效性研究不道德或不可行時(shí)，允許利用動(dòng)物研究的有效性數(shù)據(jù)作為審批時(shí)的依據(jù)，主要適用于治療或預(yù)防會(huì)危及生命的、因倫理道德或不可操作性等原因無(wú)法獲得人臨床數(shù)據(jù)的新藥和新生物制品的審批和注冊(cè)。

企業(yè)文化

 

(1) In this study, a total of 7,685,872 pig intestine gene sets were obtained and compared with that of human and mouse gut microbiomes. The results showed that there was a certain overlap between the human and pig intestine microbial groups at the gene level, The coincidence of non-bacterial bacteria in the human and swine gut microbiomes. Also, the similarity of human and porcine gut microbiota bacteria to human and mouse gut microbiomes;
(2) This article shows the effects of breed, sex and age on the composition and metabolic function of pig intestine;
(3) The antibiotic resistance gene abundance in the bacterial gut flora of continuously fed antibiotics is more bacterial than the French and Danish pigs whose use of antibiotics is prohibited. Overall, however, all of the pig intestine flora had abundant antibiotic resistance genes. Anthrax Vaccine BioThrax (Anthrax Vaccine) is a vaccine against anthrax produced by Emergent BioSolutions Inc. in the United States. The vaccine was first approved by the U.S. Food and Drug Administration (FDA) in 1970 for use only by adults at risk of exposure to Bacillus anthracis . BioThrax is prepared from Bacillus anthracis culture filtrate and since 1998 the U.S. government has procured nearly 33.5 million doses of BioThrax vaccine.
On November 24, 2015, the FDA approved BioThrax's new indications and applications. FDA approved the use of BioThrax to prevent exposure to Bacillus anthracis suspicious or diagnosed as Bacillus anthracis bacterial cases. The approval is for patients 18-65 years of age to prevent and treat anthrax bacteria by combining the recommended antibiotics.
Anthrax is a potent zoonotic infection caused by Bacillus anthracis and appears to be in three forms: cutaneous, gastrointestinal and inhaled. Inhalation-type anthrax which harms the most serious, if not treated, will be fatal. Anthrax is one of the bacterial pathogens most used by bacteriological attacks on biological weapons, mainly because anthrax spores are non-bacterial stable and easily dispersible. Although anthrax bacteria are rare, anthrax may also be infected by natural exposures, such as exposure to infected animals or contaminated animal products.
Anthrax Vaccine BioThrax is the first vaccine approved under the Animal Rule. Animal rules allow the use of data on the validity of animal studies as a basis for approval, when it is unethical or impractical to use humans for vaccine effectiveness studies and are primarily applicable to the treatment or prevention of life-threatening, ethical or inoperable And other reasons can not get the clinical data of new drugs and new biological products for approval and registration.